An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63–89.
   PubMedGoogle Scholar
• Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38–52.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials 3. J Clin Oncol. 2016;34:1402–1418.
   PubMed Web of Science ®Google Scholar
• Rescigno P, Dolling D, Conteduca V, et al. Early post-treatment prostate-specific antigen at 4 weeks and abiraterone and enzalutamide treatment for advanced prostate cancer: an international collaborative analysis. Eur Urol Oncol. 2020;3(2):176–182.
   PubMed Web of Science ®Google Scholar
• Burgio SL, Conteduca V, Rudnas B, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.
   PubMed Web of Science ®Google Scholar
• González-Billalabeitia E, Conteduca V, Wetterskog D, et al. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. Prostate Cancer Prostatic Dis. 2019;22:195–205.
   PubMed Web of Science ®Google Scholar
• Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust. 1869;14:146–147.
   Google Scholar
• Ponti G, Maccaferri M, Percesepe A, et al. Liquid biopsy with cell free DNA: new horizons for prostate cancer. Crit Rev Clin Lab Sci. 2020;17:1–17.
   Google Scholar
• Wilt TJ, Jones KM, Barry MJ, et al. Follow up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377:132–142.
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228.
   PubMed Web of Science ®Google Scholar
• Wu A, Attard G. Plasma DNA analysis in prostate cancer: opportunities for improving clinical management. Clin Chem. 2019;65(1):100–107.
   PubMed Web of Science ®Google Scholar
• Campos-Fernandez E, Barcelos LS, de Souza AG, et al. Research landscape of liquid biopsies in prostate cancer. Am J Cancer Res. 2019;9(7):1309–1328.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics driven oncology. Nat Rev Genet. 2019;20(2):71–88.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
   PubMed Web of Science ®Google Scholar
• Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33–41.
   PubMed Web of Science ®Google Scholar
• Del Re M, Biasco E, Crucitta S, et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol. 2017;71(4):680–687.
   PubMed Web of Science ®Google Scholar
• Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 2021;24(2):524–531.
   PubMed Web of Science ®Google Scholar
• McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2(7):1–8.
   Web of Science ®Google Scholar
• McKiernan J, Donovan MJ, Margolis E, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/mL at initial biopsy. Eur Urol. 2018;74:731–738.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Azad AA, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016;2(12):1598–1606.
   PubMed Web of Science ®Google Scholar
• Ulz P, Belic J, Graf R, et al. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun. 2016;7:12008.
   PubMed Web of Science ®Google Scholar
• Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–357.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Annala M, Aggarwal R, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109:12.
   Google Scholar
• Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–487.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Rosenfeld N. Circulating tumor-derived DNA is shorter than somatic DNA in plasma. Proc Natl Acad Sci USA. 2015;112:3178–3179.
   PubMed Web of Science ®Google Scholar
• Kwee S, Song M-A, Cheng I, et al. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci. 2012;5(1):65–70.
   PubMed Web of Science ®Google Scholar
• Ponti G, Maccaferri M, Manfredini M, et al. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. Clin Chim Acta. 2019;497:76–80.
   PubMed Web of Science ®Google Scholar
• Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002;48:421–427.
   PubMed Web of Science ®Google Scholar
• Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012;7:e47020.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–451.
   PubMed Web of Science ®Google Scholar
• Meddeb R, Pisareva E, Thierry AR. Guidelines for the preanalytical conditions for analyzing circulating cellfree DNA. Clin Chem. 2019;65(5):623–633.
   PubMed Web of Science ®Google Scholar
• Markus H, Contente-Cuomo T, Farooq M, et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018;8(1):7375.
   PubMedGoogle Scholar
• Kienel A, Porres D, Heidenreich A, et al. cfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer. J Urol. 2015;194:966–971.
   PubMed Web of Science ®Google Scholar
• Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA. J Clin Oncol. 2017;35:3189–3197.
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in post-docetaxel patients with metastatic castration-resistant prostate cancer–PROSELICA. J Clin Oncol. 2017;35:3198–3206.
   PubMed Web of Science ®Google Scholar
• Mehra N, Dolling D, Sumanasuriya S, et al. Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA). Eur Urol. 2018;74(3):283–291.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28:1508–1516.
   PubMed Web of Science ®Google Scholar
• Romanel A, Tandefelt DG, Conteduca V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10.
   PubMed Web of Science ®Google Scholar
• Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8:444–457.
   PubMed Web of Science ®Google Scholar
• Wu A, Cremaschi P, Wetterskog D, et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Invest. 2020;130(4):1991–2000.
   PubMed Web of Science ®Google Scholar
• Lallous N, Volik SV, Awrey S, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016;17:10.
   PubMed Web of Science ®Google Scholar
• Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Jayaram A, Romero-Laorden N, et al. Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(3):368–373.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Castro E, Wetterskog D, et al. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;116:158–168.
   PubMed Web of Science ®Google Scholar
• De Laere B, Oeyen S, Mayrhofer M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;15;25(6):1766–1773.
   Web of Science ®Google Scholar
• Ritch E, Fu SYF, Herberts C, et al. Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer. Clin Cancer Res. 2020;26(5):1114–1125.
   PubMed Web of Science ®Google Scholar
• De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–2102.
   PubMed Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26:2487–2496.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Mehra N, Higano CS, et al. TALAPRO-1: a phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) - first interim analysis (IA). J Clin Oncol. 2020;38:119.
   Google Scholar
• Smith MR, Sandhu SK, Kelly WK, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37:202.
   PubMedGoogle Scholar
• Conteduca V, Wetterskog D, Scarpi E, et al. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. Br J Cancer. 2020;123(6):982–987.
   PubMed Web of Science ®Google Scholar
• Choudhury AD, Werner L, Francini E, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018;3(21):e122109.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Poti G, Caroli P, et al. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. Ther Adv Med Oncol. 2021 Feb 24;13:1758835920987654.
   Web of Science ®Google Scholar
• Gurioli G, Conteduca V, Lolli C, et al. Plasma AR copy number changes and outcome to abiraterone and enzalutamide. Front Oncol. 2020;10:567809.
   PubMed Web of Science ®Google Scholar
• Jayaram A, Wingate A, Wetterskog D, et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial. Ann Oncol. 2021 Mar 29;S0923-7534(21)01074–7.
   PubMed Web of Science ®Google Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7(9):1006–1017.
   PubMed Web of Science ®Google Scholar
• Peter MR, Bilenky M, Isserlin R, et al. Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. Epigenomics. 2020;12(15):1317–1332.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–1209.
   PubMed Web of Science ®Google Scholar
• Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715–1722.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Caroli P, Burgio SL, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5(23):12448–12458.
   PubMedGoogle Scholar
• Schepisi G, Farolfi A, Conteduca V, et al. Immunotherapy for prostate cancer: where we are headed. Int J Mol Sci. 2017;18(12).
   PubMed Web of Science ®Google Scholar
• Conteduca V, Aieta M, Amadori D, et al. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol. 2014;92(1):11–24.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7–18.
   PubMed Web of Science ®Google Scholar
• Burgio SL, Conteduca V, Menna C, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer. 2014;21(3):487–493.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Burgio SL, Menna C, et al. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate. 2014;74(16):1691–1696.
   PubMed Web of Science ®Google Scholar
• Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653–1668.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Gurioli G, Brighi N, et al. Plasma androgen receptor in prostate cancer. Cancers (Basel). 2019;11(11):1719.
   Web of Science ®Google Scholar
• Chen X, Wang L, Lou J. Nanotechnology strategies for the analysis of circulating tumor DNA: a review. Med Sci Monit. 2020;26:e921040.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li M, Gao X, et al. Nanotechnologies in cancer diagnosis: progress, challenges, and opportunities. J Hematol Oncol. 2019;12(1):137.
   PubMed Web of Science ®Google Scholar
• Lyu N, Rajendran VK, Diefenbach RJ, et al. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. Nanotheranostics. 2020;4(4):224–232.
   PubMedGoogle Scholar
• Fu X, Wen J, Li J, et al. Highly sensitive detection of prostate cancer specific PCA3 mimic DNA using SERS-based competitive lateral flow assay. Nanoscale. 2019;11(33):15530–15536.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen F, Zhang D, et al. Single copy-sensitive electrochemical assay for circulating methylated DNA in clinical samples with ultrahigh specificity based on a sequential discrimination–amplification strategy. Chem Sci. 2017;8(7):4764–4770.
   PubMed Web of Science ®Google Scholar
• Nguyen AH, Sim SJ. Nanoplasmonic biosensor: detection and amplification of dual bio-signatures of circulating tumor DNA. Biosens Bioelectron. 2015;67:443–449.
   PubMed Web of Science ®Google Scholar